Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


Skin diseases

Research identifies potential target for treating inflammatory skin diseases

Targeting Ripk1 could be an effective treatment for skin conditions such as eczema and psoriasis, a study finds.

Inflammatory skin conditions like eczema and psoriasis are known to have a genetic component, which is often related to the tumour necrosis factor (TNF) superfamily.

In a paper in the Journal of Investigative Dermatology (15 July 2017), researchers explored the role of inhibitor of apoptosis proteins (IAPs), signalling molecules that are involved in TNF-mediated cell death, in the skin’s homeostasis[1].

In mice, they showed that IAP deletion, either in the epidermis or keratinocytes, resulted in skin inflammation and keratinocyte death resembling dermatitis. But this effect was attenuated in mice who were missing one copy of an allele called Ripk1, which encodes an enzyme involved in cell apoptosis signalling, and to a greater extent than in mice with complete absence of TNF.

The results indicate that targeting Ripk1, which is already being explored in inflammatory bowel disease, could be an effective option for treating inflammatory skin diseases and might help patients who fail to respond to TNF-inhibitors, the team concluded.

Citation: Clinical Pharmacist DOI: 10.1211/CP.2017.20203594

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.